Evolution of COVID-19 infection in four psoriatic patients treated with biological drugs.
作者信息
Conti A, Lasagni C, Bigi L, Pellacani G
机构信息
Department of Surgical, Medical, Dental and Morphological Sciences related to Transplant, Oncology and Regenerative Medicine, Dermatology Unit, University of Modena and Reggio Emilia, Modena, Italy.
出版信息
J Eur Acad Dermatol Venereol. 2020 Aug;34(8):e360-e361. doi: 10.1111/jdv.16587. Epub 2020 Jun 8.
Abstract
摘要
相似文献
1
Evolution of COVID-19 infection in four psoriatic patients treated with biological drugs.4例接受生物制剂治疗的银屑病患者的新型冠状病毒肺炎感染演变情况
J Eur Acad Dermatol Venereol. 2020 Aug;34(8):e360-e361. doi: 10.1111/jdv.16587. Epub 2020 Jun 8.
2
SARS-CoV-2 infection in a psoriatic patient treated with IL-17 inhibitor.一名接受白细胞介素-17抑制剂治疗的银屑病患者感染了新型冠状病毒。
J Eur Acad Dermatol Venereol. 2020 Aug;34(8):e357-e358. doi: 10.1111/jdv.16571. Epub 2020 Jun 8.
3
Should patients stop their biologic treatment during the COVID-19 pandemic.在新冠疫情期间，患者是否应该停止生物制剂治疗？
J Dermatolog Treat. 2020 Jun;31(4):317-318. doi: 10.1080/09546634.2020.1742438. Epub 2020 Mar 19.
4
Should biologics for psoriasis be interrupted in the era of COVID-19?在新冠疫情时代，银屑病生物制剂是否应中断使用？
J Am Acad Dermatol. 2020 May;82(5):1217-1218. doi: 10.1016/j.jaad.2020.03.031. Epub 2020 Mar 19.
5
Improvement of SARS-CoV-2 symptoms following Guselkumab injection in a psoriatic patient.一名银屑病患者注射古塞库单抗后新冠病毒症状改善。
J Eur Acad Dermatol Venereol. 2020 Aug;34(8):e363-e364. doi: 10.1111/jdv.16590. Epub 2020 Jun 4.
6
Importance of Environmental Factors on Production of Computationally- Defined Natural Molecules against COVID-19 Pandemic.环境因素对针对新冠疫情生成计算定义的天然分子的重要性。
Curr Top Med Chem. 2020;20(22):1958-1961. doi: 10.2174/156802662022200917110430.
7
COVID-19 pulmonary infection in erythrodermic psoriatic patient with oligodendroglioma: safety and compatibility of apremilast with critical intensive care management.患有少突胶质细胞瘤的红皮病型银屑病患者的COVID-19肺部感染：阿普米司特与重症监护管理的安全性和兼容性
J Eur Acad Dermatol Venereol. 2020 Aug;34(8):e376-e378. doi: 10.1111/jdv.16625. Epub 2020 Jun 4.
8
Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era.中重度斑块状银屑病患者真实世界队列的现状，以及在新冠疫情时代使用生物制剂的相关考虑。
Expert Opin Biol Ther. 2020 Aug;20(8):829-830. doi: 10.1080/14712598.2020.1779217. Epub 2020 Jun 16.
9
Effects of disruption from COVID-19 on antimalarial strategies.新冠疫情造成的干扰对疟疾防治策略的影响。
Nat Med. 2020 Sep;26(9):1334-1336. doi: 10.1038/s41591-020-1047-5.
10
Clinical outcomes of coronavirus disease 2019 (COVID-19) in cancer patients with prior exposure to immune checkpoint inhibitors.曾接触过免疫检查点抑制剂的癌症患者感染2019冠状病毒病（COVID-19）的临床结局
Cancer Commun (Lond). 2020 Aug;40(8):374-379. doi: 10.1002/cac2.12077. Epub 2020 Jul 15.
引用本文的文献
1
Management of Psoriasis Patients with Serious Infectious Diseases.严重感染性疾病银屑病患者的管理。
Adv Ther. 2024 Jun;41(6):2099-2111. doi: 10.1007/s12325-024-02873-2. Epub 2024 May 6.
2
COVID-19 Among Patients with Psoriasis: A Single-Center Retrospective Cross-Sectional Study.银屑病患者中的新型冠状病毒肺炎：一项单中心回顾性横断面研究。
Infect Dis Clin Microbiol. 2023 Jun 23;5(2):127-135. doi: 10.36519/idcm.2023.192. eCollection 2023 Jun.
3
Psoriasis and biological drugs at the time of SARS-CoV-2 infection: a mini review outlining risk of infection, seroprevalence, and safety and efficacy of the BNT162b2 vaccine.COVID-19 感染时的银屑病和生物药物：概述感染风险、血清流行率以及 BNT162b2 疫苗安全性和有效性的小型综述。
Front Immunol. 2024 Jan 30;15:1354729. doi: 10.3389/fimmu.2024.1354729. eCollection 2024.
4
A systematic review and meta-analysis of investigating the mutual impact of COVID-19 and psoriasis: Focusing on COVID-19 course in psoriasis and the opinion on biologics in this setting.一项关于探究2019冠状病毒病（COVID-19）与银屑病相互影响的系统评价和荟萃分析：聚焦银屑病患者的COVID-19病程及在此背景下对生物制剂的看法。
Immun Inflamm Dis. 2023 Nov;11(11):e1063. doi: 10.1002/iid3.1063.
5
Treatment of Moderate to Severe Psoriasis during the COVID-19 Pandemic: Lessons Learned and Opportunities.2019年冠状病毒病大流行期间中重度银屑病的治疗：经验教训与机遇
J Clin Med. 2022 Apr 26;11(9):2422. doi: 10.3390/jcm11092422.
6
Erythrodermic flare-up of psoriasis with COVID-19 infection: A report of two cases and a comprehensive review of literature focusing on the mutual effect of psoriasis and COVID-19 on each other along with the special challenges of the pandemic.银屑病红皮病型发作合并新型冠状病毒肺炎感染：两例报告及文献综述，重点关注银屑病与新型冠状病毒肺炎的相互影响以及疫情带来的特殊挑战
Clin Case Rep. 2022 Apr 20;10(4):e05722. doi: 10.1002/ccr3.5722. eCollection 2022 Apr.
7
Seroconversion after anti-SARS-CoV-2 mRNA vaccinations among moderate-to-severe psoriatic patients receiving systemic biologicals-Prospective observational cohort study.中重度银屑病患者接受系统生物制剂治疗后抗 SARS-CoV-2 mRNA 疫苗接种的血清转化率：前瞻性观察队列研究。
Dermatol Ther. 2022 May;35(5):e15408. doi: 10.1111/dth.15408. Epub 2022 Mar 5.
8
Novel Therapeutic Approaches to Psoriasis and Risk of Infectious Disease.银屑病的新型治疗方法与传染病风险
Biomedicines. 2022 Jan 21;10(2):228. doi: 10.3390/biomedicines10020228.
9
Management of Psoriasis During the Coronavirus Disease 2019 Pandemic.2019年冠状病毒病大流行期间银屑病的管理
J Clin Aesthet Dermatol. 2021 Sep;14(9):41-44.
10
Biologics for Psoriasis During the COVID-19 Pandemic.新冠疫情期间用于治疗银屑病的生物制剂
Front Med (Lausanne). 2021 Dec 6;8:759568. doi: 10.3389/fmed.2021.759568. eCollection 2021.
本文引用的文献
1
SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor.一名接受白细胞介素-23抑制剂治疗的银屑病患者感染了新型冠状病毒。
J Eur Acad Dermatol Venereol. 2020 Jun;34(6):e254-e255. doi: 10.1111/jdv.16468. Epub 2020 Jun 10.
2
Should biologics for psoriasis be interrupted in the era of COVID-19?在新冠疫情时代，银屑病生物制剂是否应中断使用？
J Am Acad Dermatol. 2020 May;82(5):1217-1218. doi: 10.1016/j.jaad.2020.03.031. Epub 2020 Mar 19.
3
[Advances in the research of mechanism and related immunotherapy on the cytokine storm induced by coronavirus disease 2019].[新型冠状病毒肺炎细胞因子风暴的机制及相关免疫治疗研究进展]
Zhonghua Shao Shang Za Zhi. 2020 Jun 20;36(6):471-475. doi: 10.3760/cma.j.cn501120-20200224-00088.
4
Reducing mortality from 2019-nCoV: host-directed therapies should be an option.降低2019新型冠状病毒所致死亡率：宿主导向疗法应成为一种选择。
Lancet. 2020 Feb 22;395(10224):e35-e36. doi: 10.1016/S0140-6736(20)30305-6. Epub 2020 Feb 5.
5
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.中国武汉地区 2019 年新型冠状病毒感染患者的临床特征。
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
6
Inhibition of the inflammatory cytokine tumor necrosis factor-alpha with etanercept provides protection against lethal H1N1 influenza infection in mice.用依那西普抑制炎性细胞因子肿瘤坏死因子-α可保护小鼠免受致死性H1N1流感感染。
Crit Care. 2013 Dec 27;17(6):R301. doi: 10.1186/cc13171.
Zotero 插件